Clinical Trials | April 22, 2026
Asahi Kasei pushes into human trials with new autoimmune drug candidate
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
The deal the group says marks a decisive push deeper into severe infectious diseases and the build-out of a global specialty pharmaceuticals platform
By cutting pain crises & boosting haemoglobin
If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev
The programme integrates simulation-based training, expert-led sessions, and case-based discussions
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
IgAN is a rare, progressive kidney disease driven by abnormal IgA immune complexes that deposit in the kidneys
The newly formed SAB will provide strategic direction across research, clinical development, and regulatory pathways
AI-enabled learning platform to enhance clinical quality, patient outcomes, and staff engagement across Eastern India network
The unit is equipped with advanced monitoring systems and supported by a multidisciplinary team
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
